Add BrightSurf on Google Email

Splicing it all together in the fight against cancer

Researchers at Osaka University have developed molecules that can correct improper splicing of a vital tumor suppressor gene in neuroendocrine cancers. The study demonstrates that these splice-switching oligonucleotides can significantly reduce viable cancer cells and tumor size in mice, suggesting a novel therapeutic approach for intr...

SourceOsaka University·TypeExperimental study·DateJul 2, 2024

New class of cancer mutations discovered in so-called ‘junk’ DNA

A new study has identified potential cancer drivers hidden in so-called 'junk' regions of DNA, which could lead to early diagnosis and new treatments. The discovery reveals mutations in previously overlooked regions of the genome that may contribute to the formation and progression of at least 12 different cancers.

SourceGarvan Institute of Medical Research·JournalNucleic Acids Research·TypeExperimental study·DateJul 2, 2024

Deep learning-assisted lesion segmentation in PET/CT imaging: A feasibility study for salvage radiation therapy in prostate cancer

Researchers explore the feasibility of deep learning models in segmenting lesions on PET/CT images to improve salvage radiation therapy planning for prostate cancer. The study demonstrates promising potential to reduce inter- and intra-observer variations, leading to more accurate treatment outcomes.

SourceImpact Journals LLC·JournalOncoscience·TypeCommentary/editorial·DateJun 28, 2024

AI model may yield better outcomes for prostate cancer

A new AI model has been shown to significantly improve the accuracy of diagnosing prostate cancer by 45 times compared to doctors' measurements alone. The system assists in mapping out the boundaries of cancerous tissue, reducing the risk of underestimation and enabling more precise treatment planning and effective surgical procedures.

Glowing dye helps surgeons eradicate prostate cancer

A glowing marker dye attached to a special marker molecule enables surgeons to visualize prostate cancer cells in real-time, allowing for more precise removal of cancerous tissues and preservation of healthy tissue. This technology has the potential to reduce the chances of cancer recurrence and minimize life-changing side effects.

SourceCancer Research UK·JournalEuropean Journal of Nuclear Medicine and Molecular Imaging·TypeExperimental study·DateJun 9, 2024

SNMMI Abstract of the Year: [177Lu]Lu-PSMA-617 extends progression-free survival with manageable safety profile in taxane-naïve advanced prostate cancer patients

[177Lu]Lu-PSMA-617 significantly improves radiographic progression-free survival and overall quality of life for patients with taxane-naive mCRPC, while minimizing adverse events. The study's findings suggest that [177Lu]Lu-PSMA-617 may change the treatment paradigm for pre-taxane advanced prostate cancer patients.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJun 9, 2024

Screening for prostate cancer with first-line MRI less cost-effective than first-line PSA testing

A cost-effectiveness analysis found that first-line MRI-based screening for prostate cancer is less effective and more costly than first-line PSA testing. Despite free MRI costs, the first-line approach resulted in increased false positives and overdiagnosis without substantial reductions in mortality.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeNews article·DateJun 3, 2024

Study assesses cancer-related care at US hospitals predominantly serving minority populations compared with non-minority serving hospitals

A study analyzing data from the National Cancer Database found that patients receiving care at minority-serving hospitals were 17% less likely to receive definitive treatment for breast cancer and up to 31% less likely for prostate, lung, and colon cancers. Improving treatment rates could lead to additional patient outcomes.

SourceWiley·JournalCancer·DateMay 27, 2024

First in-human investigator-initiated clinical trial to launch for refractory prostate cancer patients: Novel alpha therapy targets prostate-specific membrane antigen

A new alpha-ray therapeutic agent ([At-211] PSMA-5) has been developed to target prostate-specific membrane antigen (PSMA) in refractory prostate cancer patients. The therapy has shown efficacy in animal models and is now being tested in a first-in-human clinical trial.

SourceOsaka University·TypeRandomized controlled/clinical trial·DateMay 27, 2024

ASCO: Large precision oncology study identifies differences in prostate cancer genomics among a racially and ethnically diverse cohort of U.S. veterans

A genomic study of over 5,000 veterans with advanced prostate cancer reveals significant differences in frequencies of alterations associated with race and ethnicity. Alterations in immunotherapy targets were more common in Black veterans, potentially leading to opportunities for precision-based therapy.

Fred Hutch at ASCO: Progress in treating metastatic cancer, hospice access for cancer patients, use of machine learning with CAR T-cell therapy

Fred Hutch researchers present progress in treating metastatic cancer with novel therapies, including a Phase II study testing TNF-a inhibitors for castration-resistant prostate cancer. The center also explores improving hospice access and using machine learning with CAR T-cell therapy to enhance patient outcomes.

Drug helps reprogram macrophage immune cells, suppress prostate and bladder tumor growth

A novel therapy has been developed to reprogram macrophage immune cells, shifting their balance toward antitumor activity. The treatment, JHU083, blocks the use of glutamine in tumors, reducing growth and triggering cell death. It also boosts immune-activating macrophages, recruiting tumor-killing T-cells and natural killer cells.

SourceJohns Hopkins Medicine·JournalCancer Immunology Research·DateMay 21, 2024

Prostate cancer screening: longer screening intervals are safe with low baseline PSA

A new study suggests that longer screening intervals for prostate cancer are safe and effective when the initial PSA test is conducted at a young age. The PROBASE trial found that only 0.45% of men with low-risk PSA levels developed high PSA levels, indicating an increased risk of prostate cancer. This finding supports the idea of rais...

SourceGerman Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)·JournalEuropean Urology·TypeObservational study·DateMay 16, 2024

Research shows altered regulation of genes linked to prostate cancer among firefighters

A new study found that experienced firefighters have different epigenetic modifications linked to prostate cancer risk compared to new firefighters. Chemical exposure to PFAS is associated with these changes. The research team investigated fire department data and found a link between PFAS exposure and increased prostate cancer risk.

SourceUniversity of Arizona Health Sciences·JournalEnvironmental and Molecular Mutagenesis·DateMay 7, 2024

Listening to mindfulness audios during radiation improves physical, emotional side effects

Men with prostate cancer who listened to mindfulness audio recordings during radiation therapy experienced significant reductions in fatigue, sleep problems, anxiety, and depressive symptoms. The study found that the mindfulness intervention was more effective than listening to relaxing music during treatment.

SourceNorthwestern University·JournalGlobal Advances in Integrative Medicine and Health·DateApr 30, 2024

ECOG-ACRIN research at ASCO 2024

The ECOG-ACRIN Cancer Research Group will present late-breaking findings on prostate cancer, breast cancer, and pancreas cancer at ASCO 2024. These studies include optimal chemotherapy for Black women with breast cancer and results from the first randomized national trial in older adults with pancreas cancer.

New urine-based test detects high-grade prostate cancer, helping men avoid unnecessary biopsies

Researchers have developed a new urine-based test that identifies high-grade prostate cancer by analyzing 18 genes linked to the disease. The test, called MyProstateScore2.0, was shown to be nearly 100% correct at ruling out aggressive cancers and helped avoid up to 41% of unnecessary biopsies.

SourceMichigan Medicine - University of Michigan·JournalJAMA Oncology·TypeExperimental study·DateApr 18, 2024

New SPECT/CT technique shows impressive biomarker identification, offers increased access for prostate cancer patients

A novel SPECT/CT acquisition method utilizing lead-212 (212Pb) can accurately detect radiopharmaceutical biodistribution in a convenient manner. This technique has the potential to change practice and increase access for patients around the world by providing more precise treatment options.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateApr 17, 2024

Proteogenomic signatures may help identify risk of prostate cancer progression in patients with African and European ancestries

A study found that proteogenomic signatures in prostate cancer tissue from patients with African and European ancestries were associated with a higher risk of metastasis and/or recurrence. The study identified mutation signatures and recurrent copy number alterations that correlated with disease progression.

A biologic drug-device combination immunotherapy shows promise for patients with metastatic prostate cancer

A biologic drug-device combination therapy has shown promising results in treating metastatic prostate cancer, with 60% of patients experiencing an objective response. The treatment, SYNC-T, uses a cold-temperature probe to kill tumor cells and release immune-stimulating neoantigens, leading to a high response rate without severe toxic...